Title | Long term efficacy, tolerance and safety of liposo mal amphotericin b in children with CNS aspergil losis and acute lymphoblastic leukemia | |
Author | F. Athanasiadou, A. Tragiannidis, Th. Papageorgiou and M. Stamou | |
Citation | Athanasiadou, F., Tragiannidis, A., Papageorgiou, T. and Stamou, M.: Long term efficacy, tolerance and safety of liposo mal amphotericin b in children with CNS aspergil losis and acute lymphoblastic leukemia, Epitheorese Klin. Farmakol. Farmakokinet. 18(1): 85-87 (2004) | |
Publication Date | Accepted for publication: 2004 | |
Full Text Language | English | |
Order – Buy | Ηλεκτρονική Μορφή: pdf (10 €) – Digital Type: pdf (10 €) pharmakonpress[at]pharmakonpress[.]gr | |
Keywords | Central Nervous System (CNS), aspergillosis, acute lymphoblastic leukemia childhood | |
Other Terms | review article | |
Summary | Invasive fungal infections are important causes of morbidity and mortality among children receiving cancer chemotherapy or undergoing bone marrow or stem cell transplantation. Aspergillus species can cause life-threatening infections in immunocompromised and severe neutropenic pediatric patients. Cerebral aspergillosis represents the third most frequent site of invasive aspergillosis and carries a high mortality especially in immunocompromised children. We report our experience in the therapeutic management of CNS aspergillosis with a long term iv use of liposomal amphotericin B in 3 children with acute lymphoblastic leukemia (ALL) receiving remission induction therapy. Diagnosis of CNS aspergillosis was based on the clinical features (prolonged fever, severe neutropenia, vomiting, headaches), radiological and laboratory data (aspergillus DNA was detected in plasma/CSF by PCR). All children received liposomal amphotericin B for a long term (4, 10 and 12 months respectively). Based on the clinical data and laboratory/radiological exams we noticed that a favorable outcome was achieved by the prolonged use of liposomal amphotericin B with minimal infusion-related reactions and nephrotoxicity. In 2 children CNS aspergillosis lesions were eradicated, while the third one died after the discontinuation of antifungal therapy in absence of radiological findings of CNS aspergillosis. Our findings suggest that the long-term antifungal therapy with liposomal amphotericin B in children is well tolerated, effective and increases survival of these patients. | |
References | 1. Rankin N.: Disseminated aspergillosis and moniliasis associated with agranulocytosis and antibiotic therapy. Br. Med. J. 183·. 918-919 (1953)2. Groll A, Shal P, Mentzel C, Scheider M.: Changing pattern of invasive mycoses at autopsy (abstract J 109). In:
Program and abstracts of the 34,h Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: Americal Society for Microbiology, 1994 3. Swu-Jane L., Schranz J., Teutsch M.: Aspergillosis Case-Fatallty Rate: systemic review of the literature. Clin. Infect. Dis. 32. 358-366 (2001) 4. Klont R., Meis J.F., Verwij P.E.: Clinical assessment of issues in the diagnosis of invasive aspergillosis. Clin. Microbiol. Infect. 7: 32-37 (2001) 5. Atra A., Soler P., Calvagna V., Meller S.T., Riley U.R.: Successful treatment of aspergillus fungaemia in two children with acute lymphoblastic leukemia. J. Infect. 3&. 323-324 (1998) 6. Nog A., Gandong N., Kelsey A.t et al,: Successful treatment of aspergillus brain abscess in a child with acute lymphoblastic leukemia. Pediatr. Hematol. Oncol. 17: 497- 504 (2000) 7. Gozdasoglu S., Ertem M., Buyukkececi Z., Yavuzdemir S., Bengisun S., Ozenci H., et al.: Fungal colonization and infection in children with acute leukemia and lymphoma during induction therapy. Med. Pediatr. Oncol. 32.344-348 (1999) 8. Lass-Florl C., et al.: Screening for Aspergillus spp. using polymerase chain reaction of whole blood samples from patients with haematological malignancies. Br. J. Haematol. 113: 180-184 (2001) 9. Walsh T.J., Finberg R., Arndt C., et al.: Liposomal amphotericin B tor empirical therapy in patients with persistent fever and neutropenia. N. Engl. J. Med. 340: 764-771 (1999) 10. Leedders A., Daener S., Jansen R.H., et al.: Liposomal amphotericin B compared with amphotericin B deoxylate in the treatment of documented and suspected neutropenia- associated invasive fungal infections. Br. J. Haematol. 103: 205-212 (1998) 11. Walsh T., Goodman J., Pappas P., et al.: Safety, tolerance and pharmacokinetics of high-dose liposomal amphotericin B (Ampisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob. Agents Chemother. 45: 3487-3496 (2001) |
|
Relative Papers |
Online ISSN 1011-6575
Άρθρα Δημοσιευμένα σε αυτό το Περιοδικό Καταχωρούνται στα:
- Chemical Abstracts
- Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor
Articles published in this Journal are Indexed or Abstracted in: • Chemical Abstracts • Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor
Συντακτικη Επιτροπή-Editorial Board
ΕΤΗΣΙΑ ΣΥΝΔΡΟΜΗ 2004 – ANNUAL SUBSCRIPTION 2004 | |
Γλώσσα Πλήρους Κειμένου – Full Text Language | Αγγλικά – English |
Παραγγελία – Αγορά – Order – Buy | Ηλεκτρονική Μορφή: pdf (70 €) – Digital Type: pdf (70 €) pharmakonpress[at]pharmakonpress[.]gr |
Έντυπη Μορφή (70 € + έξοδα αποστολής) – Printed Type (70 € + shipping) pharmakonpress[at]pharmakonpress[.]gr |